Antibody Technology

Monoclonal Antibody Discovery for Research, Therapeutics and Diagnostics

Since our inception in 1995, Fred Hutch’s Antibody Technology shared resource has worked with research teams inside and outside the Hutch to design campaign strategies for the generation and identification of novel monoclonal antibody compositions. Our projects encompass a range of applications in oncology, viral therapeutics and diagnostics.

Submit your user feedback for Shared Resources
photo inside a robotic system in a scientific setting

Antibody Discovery

We offer full-service discovery, from target gene to antibody, in multiple host species, including mice, rats and hamsters. We use both traditional and DNA-based immunization strategies.   

Discovery Services
closeup photo of tubing and valves

Antibody Production

We can affinity purify up to 500 mg of research-grade IgG from serum-free hybridoma cultures.

Production Services
photo of a portion of machinery in a laboratory showing wires and small tubes

Antibody Characterization

Our characterization services include isotyping, variable domain sequencing, recombinant antibody validation, Western blot screening and high-throughput kinetics via Carterra LSA surface plasmon resonance.

 

Characterization Services

Our Team at Work

We work with research teams to meet each project’s specific objectives. Guided by our team’s more than 65 years of combined experience and our commitment to scientific excellence, we will assist you in designing and executing the appropriate strategy for producing the reagent you need.  

Technician looks at graph on a computer screen in a lab setting

Technician analyzes antigen-antibody binding kinetics for an epitope mapping experiment.

three-part scientific image showing the same set of cells in red, green and a combination

Insulin-secreting cells transfected with CCDC186::mCherry and co-stained with anti-mCherry and proinsulin antibodies (see Topalidou et al, PLOS Genet. 12, e1006074)

Research technician retrieves a metal rack from a large tank of liquid nitrogen in a lab setting.

Research technician retrieves samples from a cell bank. We create a frozen archive of the hit antibodies from your screen which can be evaluated for multiple lead candidates for up to five years.

Researcher works at a computer workstation next to a large robotic machine visible through a glass case

ClonePix 2 instrument prepared for a colony pick run.

Researcher views data and graphs on a computer screen in a laboratory setting.

Researcher validates the newly automated assay set-up and screening protocols.

Photo inside a laboratory with lab equipment in the foreground and a man working at the lab bench in the background.

In addition to our cutting-edge instrumentation, we have an experienced team of five scientists, such as research technician Norm Boiani, in the background.

Technician looks at graph on a computer screen in a lab setting

Technician analyzes antigen-antibody binding kinetics for an epitope mapping experiment.

three-part scientific image showing the same set of cells in red, green and a combination

Insulin-secreting cells transfected with CCDC186::mCherry and co-stained with anti-mCherry and proinsulin antibodies (see Topalidou et al, PLOS Genet. 12, e1006074)

Research technician retrieves a metal rack from a large tank of liquid nitrogen in a lab setting.

Research technician retrieves samples from a cell bank. We create a frozen archive of the hit antibodies from your screen which can be evaluated for multiple lead candidates for up to five years.

Researcher works at a computer workstation next to a large robotic machine visible through a glass case

ClonePix 2 instrument prepared for a colony pick run.

Researcher views data and graphs on a computer screen in a laboratory setting.

Researcher validates the newly automated assay set-up and screening protocols.

Photo inside a laboratory with lab equipment in the foreground and a man working at the lab bench in the background.

In addition to our cutting-edge instrumentation, we have an experienced team of five scientists, such as research technician Norm Boiani, in the background.

40

Campaigns Annually
These campaigns span antibody discovery, production and characterization.

7500

Hybridoma Lines
Many lines we’ve developed are under patent filings or used commercially.

>50

Licensed Lines
Dozens of hybridoma cell lines we’ve developed have been licensed.

How to Reach Us

Eric Tam

Eric Tam

Director, Antibody Technology shared resource

For service requests or other questions: Please submit an inquiry.

Phone: 206.667.4207
Work Location: E1-309